Australia's clinical trial advantage gains ground amid U.S. uncertainty

Uncertainty in the U.S. regulatory and funding environment is pushing more biotech and pharma companies to conduct clinical research in Australia. iNGENū reports inquiries up about 25% over last year, with U.S. sponsors accounting for most of the increase. Early-phase trials in Australia usually require no IND, ethics and regulatory approval takes about four to six weeks, and submission to first dosing can take as little as eight to 10 weeks.